The FDA recently approved a new PARP inhibitor, Talzenna (talazoparib) to be used alongside Xtandi (enzalutamide) for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. The HRR genetic mutations evaluated in the trial that led to FDA approval were ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C.

In this video, PCRI's Alex and Medical Oncologist Mark Scholz, MD, explains how Talzenna and Xtandi work, surveys side effects and side effect mitigation, and provide context for how this treatment protocol compares to other similar therapies and the situations in which a patient and his doctor may consider Talzenna + Xtandi as a treatment for his case of prostate cancer.

View the FDA approval here -- [ Ссылка ]

0:06 Talazoparib ( was recently FDA-approved alongside Xtandi (enzalutamide) for some men with advanced prostate cancer. Could you provide a background on these two drugs, Talzenna and Xtandi?

3:02 PARP inhibitors are becoming more relevant in the treatment of men with advanced prostate cancer. How do PARP inhibitors work, and what is the patient experience like when they are taking these medications?

4:06 How effective was Talzenna + Xtandi in the treatment of advanced prostate cancer?

4:40 What are the most common side effects of Talzenna + Xtandi?

5:07 Should a patient and their physician be monitoring blood counts (or any other health indicators) while on Talzenna + Xtandi?

7:27 In which patients would Talzenna + Xtandi be considered, and when should it be used?

9:55 How does Talzenna compare to other PARP inhibitors that are used in the prostate cancer space, Olaparib, and Rucaparib?

11:09 If a patient is already on another second-generation anti-androgen (for example, Zytiga, Erleada, or Nubeqa) would they need to switch to Xtandi if they wanted to add Talzenna?

--

Don’t know your stage? Take the quiz: Visit [ Ссылка ]

To learn more about prostate cancer, visit [ Ссылка ]

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: [ Ссылка ]

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #MarkScholzMD #PCRI

свернуть